Dysregulated Lipid Metabolism in Non-alcoholic Fatty Liver Disease
DOI:
https://doi.org/10.61173/rcvq8j40Keywords:
NAFLD, NASH, lipid metabolism, fatty acidAbstract
Non-alcoholic fatty liver disease (NAFLD) is a global health concern and a clinicopathological syndrome characterized by excessive fat deposition in hepatocytes. It develops in the absence of alcohol intake or other established liver-damaging factors, encompassing a spectrum from simple hepatic steatosis to non-alcoholic steatohepatitis (NASH), which may or may not progress to cirrhosis. Abnormal lipid metabolism plays a central role in NAFLD progression, driven by genetic mutations, dysregulation of transcription factors, and altered lipid species. This review introduces key genetic factors, such as TM6SF2, PNPLA3, and MBOAT7, which contribute to lipid accumulation and liver inflammation, and discusses transcription factors like SREBP1c and PPARγ that promote lipogenesis, exacerbating hepatic fat buildup. This review also explores Lipid species like triglycerides, free fatty acids, and ceramides act as signaling molecules, influencing metabolic pathways and contributing to insulin resistance, inflammation, and fibrosis. Additionally, this review discusses signaling pathways such as mTOR and AMPK modulate lipid metabolism and impact NAFLD progression. Understanding these molecular mechanisms offers potential therapeutic targets to mitigate the metabolic disturbances in NAFLD and develop effective treatments for this increasingly prevalent disease.References
[1] Younossi, Zobair M et al. “Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes.” Hepatology (Baltimore, Md.) vol. 64,1 (2016): 73-84.
[2] Rui, Liangyou, and Jiandie D Lin. “Reprogramming of Hepatic Metabolism and Microenvironment in Nonalcoholic Steatohepatitis.” Annual review of nutrition vol. 42 (2022): 91- 113.
[3] Loomba, Rohit, and Leon A Adams. “The 20% Rule of NASH Progression: The Natural History of Advanced Fibrosis and Cirrhosis Caused by NASH.” Hepatology (Baltimore, Md.) vol. 70,6 (2019): 1885-1888.
[4] Ertle, Judith et al. “Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis.” International journal of cancer vol. 128,10 (2011): 2436-43.
[5] Palomer, Xavier et al. “An overview of the crosstalk between inflammatory processes and metabolic dysregulation during diabetic cardiomyopathy.” International journal of cardiology vol. 168,4 (2013): 3160-72.
[6] Li, Yue et al. “A global perspective on FOXO1 in lipid metabolism and lipid-related diseases.” Progress in lipid research vol. 66 (2017): 42-49.
[7] Longo, Miriam et al. “TM6SF2/PNPLA3/MBOAT7 Loss-of- Function Genetic Variants Impact on NAFLD Development and Progression Both in Patients and in In Vitro Models.” Cellular and molecular gastroenterology and hepatology vol. 13,3 (2022): 759-788.
[8] Kozlitina, Julia et al. “Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease.” Nature genetics vol. 46,4 (2014): 352-6.
[9] Kathiresan, Sekar et al. “Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans.” Nature genetics vol. 40,2 (2008): 189-97.
[10] Gorden, Alexis et al. “Genetic variation at NCAN locus is associated with inflammation and fibrosis in non-alcoholic fatty liver disease in morbid obesity.” Human heredity vol. 75,1 (2013): 34-43.
[11] Mahdessian, Hovsep et al. “TM6SF2 is a regulator of liver fat metabolism influencing triglyceride secretion and hepatic lipid droplet content.” Proceedings of the National Academy of Sciences of the United States of America vol. 111,24 (2014): 8913-8.
[12] Sookoian, Silvia, and Carlos J Pirola. “PNPLA3, the triacylglycerol synthesis/hydrolysis/storage dilemma, and nonalcoholic fatty liver disease.” World journal of gastroenterology vol. 18,42 (2012): 6018-26.
[13] Romeo, Stefano et al. “Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease.” Nature genetics vol. 40,12 (2008): 1461-5.
[14] Meroni, Marica et al. “Mboat7 down-regulation by hyper-insulinemia induces fat accumulation in hepatocytes.” EBioMedicine vol. 52 (2020): 102658.
[15] Ou, J et al. “Unsaturated fatty acids inhibit transcription of the sterol regulatory element-binding protein-1c (SREBP-1c) gene by antagonizing ligand-dependent activation of the LXR.” Proceedings of the National Academy of Sciences of the United States of America vol. 98,11 (2001): 6027-32.
[16] Kohjima, Motoyuki et al. “SREBP-1c, regulated by the insulin and AMPK signaling pathways, plays a role in nonalcoholic fatty liver disease.” International journal of Dean&Francis ISSN 2959-409X molecular medicine vol. 21,4 (2008): 507-11.
[17] Ann V., Hertzel T.D.O.C., Bernlohr D.A. Chapter 6-Lipid receptors and signaling in adipose tissue. In: Ntambi J.M., editor. Lipid Signaling and Metabolism. Volume 2020. Academic Press; Cambridge, MA, USA: 2020. pp. 99–114.
[18] Utzschneider, Kristina M, and Steven E Kahn. “Review: The role of insulin resistance in nonalcoholic fatty liver disease.” The Journal of clinical endocrinology and metabolism vol. 91,12 (2006): 4753-61.
[19] Sozen, Erdi et al. “Cholesterol accumulation in hepatocytes mediates IRE1/p38 branch of endoplasmic reticulum stress to promote nonalcoholic steatohepatitis.” Free radical biology & medicine vol. 191 (2022): 1-7.
[20] Chaurasia, Bhagirath, and Scott A Summers. “Ceramides in Metabolism: Key Lipotoxic Players.” Annual review of physiology vol. 83 (2021): 303-330.
[21] Pagadala, Mangesh et al. “Role of ceramides in nonalcoholic fatty liver disease.” Trends in endocrinology and metabolism: TEM vol. 23,8 (2012): 365-71.
[22] Gill, J M R, and N Sattar. “Ceramides: a new player in the inflammation-insulin resistance paradigm?.” Diabetologia vol. 52,12 (2009): 2475-7.
[23] Yoshida, Tomoaki et al. “Blocking sphingosine 1-phosphate receptor 2 accelerates hepatocellular carcinoma progression in a mouse model of NASH.” Biochemical and biophysical research communications vol. 530,4 (2020): 665-672.
[24] Fang, Chunqiu et al. “The AMPK pathway in fatty liver disease.” Frontiers in physiology vol. 13 970292. 25 Aug. 2022.
[25] Boudaba, Nadia et al. “AMPK Re-Activation Suppresses Hepatic Steatosis but its Downregulation Does Not Promote Fatty Liver Development.” EBioMedicine vol. 28 (2018): 194- 209.
[26] Herzig, Sébastien, and Reuben J Shaw. “AMPK: guardian of metabolism and mitochondrial homeostasis.” Nature reviews. Molecular cell biology vol. 19,2 (2018): 121-135.
[27] Zeqiraj, Elton et al. “Structure of the LKB1-STRAD-MO25 complex reveals an allosteric mechanism of kinase activation.” Science (New York, N.Y.) vol. 326,5960 (2009): 1707-11.
[28] Smith, Brennan K et al. “Treatment of nonalcoholic fatty liver disease: role of AMPK.” American journal of physiology. Endocrinology and metabolism vol. 311,4 (2016): E730-E740.
[29] Zhou, Jiaming et al. “The Nrf2 Pathway in Liver Diseases.” Frontiers in cell and developmental biology vol. 10 826204. 10 Feb. 202.
[30] Lee, Da Hyun et al. “SQSTM1/p62 activates NFE2L2/ NRF2 via ULK1-mediated autophagic KEAP1 degradation and protects mouse liver from lipotoxicity.” Autophagy vol. 16,11 (2020): 1949-1973.
[31] Friedman, Scott L et al. “Mechanisms of NAFLD development and therapeutic strategies.” Nature medicine vol. 24,7 (2018): 908-922.
[32] Marcondes-de-Castro, Ilitch Aquino et al. “AMPK/mTOR pathway significance in healthy liver and non-alcoholic fatty liver disease and its progression.” Journal of gastroenterology and hepatology vol. 38,11 (2023): 1868-1876.
[33] Bidault, Guillaume et al. “SREBP1-induced fatty acid synthesis depletes macrophages antioxidant defences to promote their alternative activation.” Nature metabolism vol. 3,9 (2021): 1150-1162.
[34] Lee, Jooho et al. “Epigenetics in non-alcoholic fatty liver disease.” Molecular aspects of medicine vol. 54 (2017): 78-88.
[35] Tang, Yuefeng et al. “Adipose tissue mTORC2 regulates ChREBP-driven de novo lipogenesis and hepatic glucose metabolism.” Nature communications vol. 7 11365. 21 Apr. 2016,
[36] Lawitz, Eric J et al. “Acetyl-CoA Carboxylase Inhibitor GS-0976 for 12 Weeks Reduces Hepatic De Novo Lipogenesis and Steatosis in Patients With Nonalcoholic Steatohepatitis.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association vol. 16,12 (2018): 1983-1991.e3.
[37] Pawlak, Michal et al. “Molecular mechanism of PPARα action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease.” Journal of hepatology vol. 62,3 (2015): 720-33.
[38] Birkenfeld, Andreas L et al. “Myocardial metabolism in heart failure: Purinergic signalling and other metabolic concepts.” Pharmacology & therapeutics vol. 194 (2019): 132- 144.
[39] Pei, Ke et al. “An Overview of Lipid Metabolism and Nonalcoholic Fatty Liver Disease.” BioMed research international vol. 2020 4020249. 18 Jul. 2020.
[40] Ren, Meiling et al. “Simultaneously targeting SOAT1 and CPT1A ameliorates hepatocellular carcinoma by disrupting lipid homeostasis.” Cell death discovery vol. 7,1 125. 29 May. 2021.
[41] Papazyan, Romeo et al. “FXR activation by obeticholic acid or nonsteroidal agonists induces a human-like lipoprotein cholesterol change in mice with humanized chimeric liver.” Journal of lipid research vol. 59,6 (2018): 982-993.
[42] Zhou, Jiyu et al. “SUMOylation inhibitors synergize with FXR agonists in combating liver fibrosis.” Nature communications vol. 11,1 240. 13 Jan. 2020.
[43] Musso, Giovanni et al. “Bioactive Lipid Species and Metabolic Pathways in Progression and Resolution of Nonalcoholic Steatohepatitis.” Gastroenterology vol. 155,2 (2018): 282-302.e8.
[44] Ratziu, Vlad et al. “Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening.” Gastroenterology vol. 150,5 (2016): 1147-1159.e5.
[45] Greco, Dario et al. “Gene expression in human NAFLD.” American journal of physiology. Gastrointestinal and liver physiology vol. 294,5 (2008): G1281-7.
[46] Seki, Hiroyuki et al. “Omega-3 PUFA derived anti- Dean&Francis Jiasheng Zeng inflammatory lipid mediator resolvin E1.” Prostaglandins & other lipid mediators vol. 89,3-4 (2009): 126-30.
[47] Yki-Järvinen, Hannele. “Nutritional Modulation of Non- Alcoholic Fatty Liver Disease and Insulin Resistance.” Nutrients vol. 7,11 9127-38. 5 Nov. 2015.
[48] Schugar, Rebecca C, and Peter A Crawford. “Lowcarbohydrate ketogenic diets, glucose homeostasis, and nonalcoholic fatty liver disease.” Current opinion in clinical nutrition and metabolic care vol. 15,4 (2012): 374-80.
[49] Pagano, Gianfranco et al. “Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic association.” Hepatology (Baltimore, Md.) vol. 35,2 (2002): 367-72.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 by the authors.
This work is licensed under a Creative Commons Attribution 4.0 International License.
